Fluence Pharma Private Limited

Board approved acquisition of 58% stake in Fluence Pharma at ~₹135 Cr enterprise value via secondary purchase. Fluence Pharma reported ~₹40 Cr FY26 revenue with 20%+ EBITDA margin from patented nutrac